JP7721142B2 - Masp-2阻害剤および使用方法 - Google Patents
Masp-2阻害剤および使用方法Info
- Publication number
- JP7721142B2 JP7721142B2 JP2022533447A JP2022533447A JP7721142B2 JP 7721142 B2 JP7721142 B2 JP 7721142B2 JP 2022533447 A JP2022533447 A JP 2022533447A JP 2022533447 A JP2022533447 A JP 2022533447A JP 7721142 B2 JP7721142 B2 JP 7721142B2
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- compound
- unsubstituted
- aryl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962943629P | 2019-12-04 | 2019-12-04 | |
| US62/943,629 | 2019-12-04 | ||
| PCT/US2020/063391 WO2021113698A1 (en) | 2019-12-04 | 2020-12-04 | Masp-2 inhibitors and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023504541A JP2023504541A (ja) | 2023-02-03 |
| JP2023504541A5 JP2023504541A5 (cg-RX-API-DMAC7.html) | 2023-10-05 |
| JP7721142B2 true JP7721142B2 (ja) | 2025-08-12 |
Family
ID=74106147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022533447A Active JP7721142B2 (ja) | 2019-12-04 | 2020-12-04 | Masp-2阻害剤および使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US12030853B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4069676A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7721142B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020395306B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3159159A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021113698A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019231935A1 (en) | 2018-05-29 | 2019-12-05 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| CN115052862A (zh) | 2019-12-04 | 2022-09-13 | 奥默罗斯公司 | Masp-2抑制剂和使用方法 |
| BR112022010895A2 (pt) | 2019-12-04 | 2022-09-06 | Omeros Corp | Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan |
| JP7699389B2 (ja) | 2019-12-04 | 2025-06-27 | オメロス コーポレーション | Masp-2阻害剤および使用方法 |
| AU2020395306B2 (en) * | 2019-12-04 | 2025-04-24 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| TWI867422B (zh) | 2020-03-06 | 2024-12-21 | 美商奥默羅斯公司 | 用於治療和/或預防流感病毒誘導的急性呼吸窘迫症候群、肺炎或者流感病毒感染的一些其它肺部表現的抑制masp-2的方法 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010515729A (ja) | 2007-01-10 | 2010-05-13 | アイアールエム・リミテッド・ライアビリティ・カンパニー | チャネル活性化プロテアーゼ阻害剤としての化合物および組成物 |
| JP2014506877A (ja) | 2011-01-04 | 2014-03-20 | ノバルティス アーゲー | 加齢性黄斑変性症(amd)の処置に有用なインドール化合物またはそのアナログ |
| JP2017508789A (ja) | 2014-02-25 | 2017-03-30 | アキリオン ファーマシューティカルズ,インコーポレーテッド | 補体媒介障害の治療のための化合物 |
| WO2019186164A1 (en) | 2018-03-29 | 2019-10-03 | University Of Leeds | Factor xiia inhibitors |
| WO2019211585A1 (en) | 2018-04-30 | 2019-11-07 | University Of Leeds | FACTOR XIIa INHIBITORS |
| JP2022552048A (ja) | 2019-08-21 | 2022-12-15 | カルビスタ・ファーマシューティカルズ・リミテッド | 酵素阻害剤 |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5453566A (en) | 1986-03-28 | 1995-09-26 | Calgene, Inc. | Antisense regulation of gene expression in plant/cells |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| ATE115999T1 (de) | 1987-12-15 | 1995-01-15 | Gene Shears Pty Ltd | Ribozyme. |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8822492D0 (en) | 1988-09-24 | 1988-10-26 | Considine J | Apparatus for removing tumours from hollow organs of body |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| DE69030172T2 (de) | 1990-01-26 | 1997-06-19 | Immunomedics Inc | Impfstoffe gegen Krebs und Infektionskrankheiten |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| IL108367A0 (en) | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| SE9301916D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptides derivatives |
| SE9301911D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptide derivatives |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| ZA951617B (en) | 1994-03-04 | 1997-02-27 | Lilly Co Eli | Antithrombotic agents. |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| US5739119A (en) | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
| US5866573A (en) | 1997-04-21 | 1999-02-02 | Merck & Co., Inc. | Pyrazinone thrombin inhibitors |
| EP1082324A4 (en) | 1998-05-26 | 2002-01-02 | Merck & Co Inc | IMIDAZOPYRIDINE COMPOUNDS AS THROMBINE INHIBITORS |
| KR20000047461A (ko) | 1998-12-29 | 2000-07-25 | 성재갑 | 트롬빈 억제제 |
| AU3192500A (en) | 1999-03-16 | 2000-10-04 | C & C Research Laboratories | Substituted proline derivatives and medicinal compositions containing the same |
| HUP0202191A3 (en) | 1999-05-19 | 2003-02-28 | Pharmacia Corp Chicago | Substituted polycyclic aryl and heteroaryl pirazinones useful for selective inhibition of the coagulation cascade and pharmaceutical compositions containing them |
| US6653316B1 (en) | 1999-05-19 | 2003-11-25 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade |
| US6664255B1 (en) | 1999-05-19 | 2003-12-16 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade |
| US7015230B1 (en) | 1999-05-19 | 2006-03-21 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade |
| US20040072862A1 (en) | 1999-06-04 | 2004-04-15 | Bitler Catherine M. | Compositions for treating ischemia-related neuronal damage |
| US6649592B1 (en) | 2000-01-14 | 2003-11-18 | Science & Technology Corporation @ Unm | Peptide inhibitors of LFA-1/ICAM-1 interaction |
| WO2001079195A2 (en) | 2000-04-14 | 2001-10-25 | Corvas International, Inc. | Pyridine and pyrazine derivatives as thrombin inhibitors |
| WO2001087851A1 (en) | 2000-05-18 | 2001-11-22 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| GB0012795D0 (en) | 2000-05-25 | 2000-07-19 | Novartis Ag | Organic compounds |
| CO5170524A1 (es) | 2000-05-29 | 2002-06-27 | Monsanto Co | Arilo policiclico y pirazinonas de heteroarilo sustituidos utiles para la inhibicion selectiva de la cascada de coagulacion |
| CO5160330A1 (es) | 2000-05-30 | 2002-05-30 | Monsanto Co | Reemplazo de arilo policiclico y heteroarilo pirimidinonas utiles para la inhibicion selectiva de una coagulacion en cascada |
| JP2004516286A (ja) | 2000-12-18 | 2004-06-03 | メルク エンド カムパニー インコーポレーテッド | ベンジルアミン誘導体およびそれのトロンビン阻害薬としての使用 |
| MXPA04003169A (es) | 2001-10-03 | 2004-07-08 | Pharmacia Corp | Profarmacos de compuestos policiclicos sustituidos utiles para inhibicion selectiva de la cascada de coagulacion. |
| CA2462647A1 (en) | 2001-10-03 | 2003-04-10 | Michael S. South | 6-membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade |
| EP1531757B1 (en) | 2002-07-19 | 2016-09-07 | Omeros Corporation | Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from |
| AU2003299901A1 (en) | 2002-10-04 | 2004-05-04 | Merck And Co., Inc. | Thrombin inhibitors |
| US20060128613A1 (en) | 2003-03-12 | 2006-06-15 | The Procter & Gamble Company | Melanocortin receptor ligands |
| US7482376B2 (en) | 2003-07-03 | 2009-01-27 | 3-Dimensional Pharmaceuticals, Inc. | Conjugated complement cascade inhibitors |
| US20140056873A1 (en) | 2004-06-10 | 2014-02-27 | University Of Leicester | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
| EP2465534B1 (en) | 2004-06-10 | 2017-03-29 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| DE602006010834D1 (de) | 2005-03-16 | 2010-01-14 | Janssen Pharmaceutica Nv | Neue thiophensulfoximine zur behandlung von komplementvermittelten krankheiten und leiden |
| EP2029553A1 (en) | 2006-05-22 | 2009-03-04 | Janssen Pharmaceutica, N.V. | Substituted pyrazinone derivatives for use as a medicine |
| TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
| EP3150635A3 (en) | 2009-10-16 | 2017-06-21 | Omeros Corporation | Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation |
| HUP1000366A2 (en) | 2010-07-13 | 2012-03-28 | Mta Enzimologiai Intezet | Novel proteins, their production process and use tereof |
| DK2694108T3 (en) | 2011-04-08 | 2018-08-20 | Univ Leicester | METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| HUE049154T2 (hu) | 2011-05-04 | 2020-09-28 | Omeros Corp | Készítmények a MASP-2-függõ komplement-aktiválás gátlására |
| AU2013201779B2 (en) | 2011-05-04 | 2016-01-07 | Omeros Corporation | Compositions for inhibiting MASP-2 dependent complement activation |
| PL2718290T3 (pl) | 2011-06-07 | 2016-11-30 | Kompozycje i sposoby modulowania kinazy | |
| KR102438072B1 (ko) | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| NZ629675A (en) | 2012-04-06 | 2017-02-24 | Omeros Corp | Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for treatment of paroxysmal nocturnal hemoglobinuria |
| PT2861246T (pt) | 2012-06-18 | 2021-04-05 | Univ Leicester | Composições e métodos para inibir masp-1 e/ou masp-2 e/ou masp-3 para o tratamento de várias doenças e perturbações |
| AR091490A1 (es) | 2012-06-19 | 2015-02-11 | Bristol Myers Squibb Co | Antagonistas de iap |
| WO2014057069A1 (en) | 2012-10-10 | 2014-04-17 | Novo Nordisk Health Care Ag | Liquid pharmaceutical composition of factor vii polypeptide |
| EP2922535B1 (en) | 2012-11-20 | 2021-11-10 | Merck Sharp & Dohme Corp. | Thrombin inhibitors |
| RS61351B1 (sr) | 2013-10-17 | 2021-02-26 | Omeros Corp | Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2 |
| US10266515B2 (en) | 2013-12-30 | 2019-04-23 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| CN117398458A (zh) | 2015-11-09 | 2024-01-16 | 奥默罗斯公司 | 用于治疗与masp-2依赖性补体活化相关的病况的方法 |
| CA3010593C (en) | 2016-01-05 | 2024-02-13 | University Of Leicester | Methods for inhibiting fibrosis in a subject in need thereof |
| US20170253667A1 (en) | 2016-01-05 | 2017-09-07 | University Of Leicester | Methods for inhibiting fibrosis in a subject in need thereof |
| NZ745531A (en) | 2016-03-31 | 2020-09-25 | Omeros Corp | Methods for inhibiting angiogenesis in a subject in need thereof |
| JOP20170170B1 (ar) | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
| US20180105604A1 (en) | 2016-10-13 | 2018-04-19 | University Of Leicester | Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy |
| TWI818919B (zh) | 2017-08-15 | 2023-10-21 | 美商歐米諾斯公司 | 用於治療和/ 或預防與造血幹細胞移植有關的移植物抗宿主病和/ 或瀰漫性肺泡出血和/ 或靜脈閉塞性病的方法 |
| BR112020004800A2 (pt) | 2017-09-13 | 2020-09-24 | Amgen Inc. | compostos de bisamida ativantes do sarcômero e seus usos |
| WO2019231935A1 (en) | 2018-05-29 | 2019-12-05 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| BR112022010895A2 (pt) | 2019-12-04 | 2022-09-06 | Omeros Corp | Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan |
| JP7699389B2 (ja) | 2019-12-04 | 2025-06-27 | オメロス コーポレーション | Masp-2阻害剤および使用方法 |
| CN115052862A (zh) | 2019-12-04 | 2022-09-13 | 奥默罗斯公司 | Masp-2抑制剂和使用方法 |
| AU2020395306B2 (en) | 2019-12-04 | 2025-04-24 | Omeros Corporation | MASP-2 inhibitors and methods of use |
-
2020
- 2020-12-04 AU AU2020395306A patent/AU2020395306B2/en active Active
- 2020-12-04 WO PCT/US2020/063391 patent/WO2021113698A1/en not_active Ceased
- 2020-12-04 EP EP20834036.4A patent/EP4069676A1/en active Pending
- 2020-12-04 CA CA3159159A patent/CA3159159A1/en active Pending
- 2020-12-04 JP JP2022533447A patent/JP7721142B2/ja active Active
- 2020-12-04 US US17/112,873 patent/US12030853B2/en active Active
-
2024
- 2024-05-31 US US18/680,563 patent/US12692229B2/en active Active
- 2024-05-31 US US18/679,774 patent/US12703684B2/en active Active
-
2025
- 2025-03-05 US US19/071,565 patent/US20250197349A1/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010515729A (ja) | 2007-01-10 | 2010-05-13 | アイアールエム・リミテッド・ライアビリティ・カンパニー | チャネル活性化プロテアーゼ阻害剤としての化合物および組成物 |
| JP2014506877A (ja) | 2011-01-04 | 2014-03-20 | ノバルティス アーゲー | 加齢性黄斑変性症(amd)の処置に有用なインドール化合物またはそのアナログ |
| JP2017508789A (ja) | 2014-02-25 | 2017-03-30 | アキリオン ファーマシューティカルズ,インコーポレーテッド | 補体媒介障害の治療のための化合物 |
| WO2019186164A1 (en) | 2018-03-29 | 2019-10-03 | University Of Leeds | Factor xiia inhibitors |
| WO2019211585A1 (en) | 2018-04-30 | 2019-11-07 | University Of Leeds | FACTOR XIIa INHIBITORS |
| JP2022552048A (ja) | 2019-08-21 | 2022-12-15 | カルビスタ・ファーマシューティカルズ・リミテッド | 酵素阻害剤 |
Non-Patent Citations (1)
| Title |
|---|
| REGISTRY(STN)[online],2011.12.05-2004.09.21, [検索日] 2024.07.31 CAS登録番号 749177-11-5, 1348395-03-8, 1348431-17-3, 1348728-96-0, 1348730-54-0 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20240351980A1 (en) | 2024-10-24 |
| US12703684B2 (en) | 2026-08-11 |
| US20240317682A1 (en) | 2024-09-26 |
| US20250197349A1 (en) | 2025-06-19 |
| AU2020395306B2 (en) | 2025-04-24 |
| JP2023504541A (ja) | 2023-02-03 |
| US12692229B2 (en) | 2026-07-28 |
| CA3159159A1 (en) | 2021-06-10 |
| AU2020395306A1 (en) | 2022-06-30 |
| US12030853B2 (en) | 2024-07-09 |
| EP4069676A1 (en) | 2022-10-12 |
| US20210171461A1 (en) | 2021-06-10 |
| WO2021113698A1 (en) | 2021-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12486278B2 (en) | MASP-2 inhibitors and methods of use | |
| JP7721143B2 (ja) | Masp-2阻害剤および使用方法 | |
| US12030853B2 (en) | MASP-2 inhibitors and methods of use | |
| JP7699389B2 (ja) | Masp-2阻害剤および使用方法 | |
| AU2023266363A1 (en) | MASP-2 inhibitors and methods of use | |
| US20240228499A1 (en) | Masp-2 inhibitors and methods of use | |
| TW202523310A (zh) | Masp-2抑制劑及其使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220808 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221021 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230927 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230927 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240215 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240822 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241001 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241227 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250327 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250626 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250707 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250723 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7721142 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |